about
The oleocanthal-based homovanillyl sinapate as a novel c-Met inhibitorA phase I dose escalation study of oral c-MET inhibitor tivantinib (ARQ 197) in combination with gemcitabine in patients with solid tumors.Analysis of circulating adipokines in patients newly diagnosed with solid cancer: Associations with measures of adiposity and tumor characteristics.Olive phenolics as c-Met inhibitors: (-)-Oleocanthal attenuates cell proliferation, invasiveness, and tumor growth in breast cancer modelsThe Hepatocyte Growth Factor Receptor: Structure, Function and Pharmacological Targeting in CancerMedullary thyroid carcinoma: molecular signaling pathways and emerging therapiesReceptor-tyrosine-kinase-targeted therapies for head and neck cancer.Novel Role for γ-Catenin in the Regulation of Cancer Cell Migration via the Induction of Hepatocyte Growth Factor Activator Inhibitor Type 1 (HAI-1).Down-regulation of CMTM8 induces epithelial-to-mesenchymal transition-like changes via c-MET/extracellular signal-regulated kinase (ERK) signaling.Targeting the HGF/Met signalling pathway in cancer.Overexpression of MET is a new predictive marker for anti-EGFR therapy in metastatic colorectal cancer with wild-type KRAS.Targeting the MET pathway for potential treatment of NSCLC.NPS-1034, a novel MET inhibitor, inhibits the activated MET receptor and its constitutively active mutants.Potential Antitumor Activity of SIM-89 in Non-Small Cell Lung Cancer Cells.Targeting met mediated epithelial-mesenchymal transition in the treatment of breast cancer.Dramatic antitumor effects of the dual MET/RON small-molecule inhibitor LY2801653 in non-small cell lung cancer.γ-Tocotrienol inhibits HGF-dependent mitogenesis and Met activation in highly malignant mammary tumour cells.c-Met inhibitors.C. elegans and mutants with chronic nicotine exposure as a novel model of cancer phenotype.
P2860
Q28821187-ED6D26CA-0E97-4B7A-B8AB-CE8F7D396429Q33414632-EDF49D31-4E86-451A-8DAA-6652D3C5FD15Q33597638-CAE5C63C-FA7F-4E42-9E41-770E0614B4B2Q33645135-F7143C44-D51A-43A0-80A6-342E81BBFD45Q34141913-E4438DF3-068A-4613-B5F3-38B9F4989ED2Q35038893-B9145EC5-772D-43CF-BC05-F63CA2C2CCC6Q35102025-EFC95045-7B11-4438-A259-ADA3DD92C758Q35860664-FF4E83F4-4773-49EE-9E86-247A591C33EBQ35874388-DD84D41F-AD10-44FB-B649-126EF0A60731Q36142604-CA989628-701A-4F2A-B1F7-C5B5CC809E0DQ37663252-337F0F5F-E776-4609-AF8F-18B64241187DQ38297235-2590B937-E811-4C9D-AD4C-3F9C93E3DCDFQ38445359-B8CD9D08-843E-410C-9C85-66D0A54507B3Q38711090-97280CDE-5290-4CFB-AA74-EF3D31431456Q38757070-21AB3A28-1641-4951-9B4C-5F4882D412B2Q39048792-2A0A1064-D1B5-4D30-AF80-EAEFDCBF543FQ39463034-A8DECEEB-E7EC-40AA-91ED-0772861F186FQ43195484-BFCA44CB-CCE7-495D-82FF-629ACF1810E4Q46591244-B864AA5D-7E71-4884-B99E-D60AA2316420
P2860
description
2009 nî lūn-bûn
@nan
2009 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
The MET axis as a therapeutic target
@nl
The MET axis as a therapeutic target.
@ast
The MET axis as a therapeutic target.
@en
type
label
The MET axis as a therapeutic target
@nl
The MET axis as a therapeutic target.
@ast
The MET axis as a therapeutic target.
@en
prefLabel
The MET axis as a therapeutic target
@nl
The MET axis as a therapeutic target.
@ast
The MET axis as a therapeutic target.
@en
P2860
P3181
P1476
The MET axis as a therapeutic target.
@en
P2093
Martin Sattler
P2860
P304
P3181
P356
10.1016/J.UCT.2009.01.001
P50
P577
2009-04-01T00:00:00Z